Immuno-Oncology Assays Market size is growing with a CAGR of 11.4% in the prediction period and it crosses USD 11.82 Bn by 2032 from USD 5.55 Bn in 2025.

The Global Immuno-Oncology Assays Market Report is Segmented by Product (Reagents & Antibodies, Instruments, and More), Technology (Immunoassay, PCR, and More), Assay Type (CDx, Ldts, RUO), Indication (Lung, Colorectal, Melanoma, Breast, Other Cancers), Sample Type (Tissue, Liquid Biopsy), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

The global Immuno Oncology Assays Market size was valued USD 5.15 billion in 2023 and is expected to rise to USD 12.74 billion by 2032 at a CAGR of 10.6%.

The global immuno-oncology assays market is expected to increase significantly up to some **** billion U.S. dollars by the begin of the next decade. This market is mainly segmented into two product types: consumables and software. The major application areas of immuno-oncology assays products are research applications and clinical diagnostics.

Market Research Intellect's Immuno Oncology Assays Market Report highlights a valuation of USD 3.5 billion in 2024 and anticipates growth to USD 7.8 billion by 2033, with a CAGR of 9.6% from 2026-2033.Explore insights on demand dynamics, innovation pipelines, and competitive landscapes.

The immuno-oncology assays market is booming, projected to reach $11.3 billion by 2033, driven by immunotherapy advancements and personalized medicine. Explore market trends, key players (Thermo Fisher, Roche), and regional growth in this detailed analysis.

The global immuno oncology assays market size is set to increase from USD 3.84 billion in 2024 to USD 6.62 billion by 2034, with a projected CAGR exceeding 5.6% from 2025 to 2034. Top companies in the industry include Agilent Technologies,, PerkinElmer,, Illumina,, Thermo Fisher Scientific,, Crown Bioscience, Merck & Company,, InSphero, F.Hoffmann-La Roche., HTG Molecular Diagnostics,.

The North America Immuno Oncology Assays report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities, allowing businesses to tailor their market entry strategies and maximize growth in specific regions.

In 2024, Market Research Intellect valued the Immuno Oncology Assays Kit Market Report at USD 3.5 billion, with expectations to reach USD 8.2 billion by 2033 at a CAGR of 12.9%.Understand drivers of market demand, strategic innovations, and the role of top competitors.

Discover the booming immuno-oncology assays market! This in-depth analysis reveals a CAGR of 12.30%, driven by NGS technology, personalized medicine, and rising cancer prevalence. Explore market size, segmentation by product, technology & indication, key players (Agilent, Thermo Fisher, Illumina), and regional trends across North America, Europe, and Asia Pacific. Forecast to 2033. Recent developments include: September 2022: The US FDA approved Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) aid in selecting patients. They do it with the help of RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced or metastatic thyroid cancer, and RET-mutation positive advanced or metastatic medullary thyroid cancer (MTC) who may be eligible for treatment with Lilly's Retevmo (selpercatinib)., June 2022: Agilent Technologies Inc. received approval from the South Korea Ministry of Food and Drug Safety (MFDS) for the company's PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients with non-small cell lung cancer (NSCLC). It is suitable for first-line monotherapy with KEYTRUDA (pembrolizumab) on the Dako Omnis platform.. Key drivers for this market are: Rising Incidence of Cancer Globally, Increasing Adoption of Targeted Therapy. Potential restraints include: Rising Incidence of Cancer Globally, Increasing Adoption of Targeted Therapy. Notable trends are: Immunoassay Segment is Expected to Have Significant Share in the Market Over the Forecast Period.

Get comprehensive Immuno Oncology Assays Market intelligence reports covering size, share, and growth trends. Access syndicated research data to make informed business decisions with expert analysis.

The report on Immuno Oncology Assays covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications. The report enables customers to recognize key drivers that influence and govern the market.

The Immuno Oncology Assay Market is estimated to be valued at USD 6.3 billion in 2025 and is projected to reach USD 19.2 billion by 2035, registering a compound annual growth rate (CAGR) of 11.8% over the forecast period.

Immuno Oncology Assays Market Advanced Research Analysis Report By Product (Consumables, Software)

Experience robust growth in the Global Immuno-Oncology Assay Market at 11.25% CAGR from 2025-30, driven by rising cancer cases & advanced diagnostics

The Immuno Oncology Assays Market size is expected to reach USD 6.9 billion in 2040 registering a CAGR of 10.5. This Immuno Oncology Assays Market research report highlights market share, competitive analysis, demand dynamics, and future growth.

Market Research Intellect presents the Immuno Oncology Assays Market Report-estimated at USD 5.2 billion in 2024 and predicted to grow to USD 12.8 billion by 2033, with a CAGR of 10.5% over the forecast period. Gain clarity on regional performance, future innovations, and major players worldwide.

The Immuno-Oncology Assays Kit market is booming, projected to reach [estimated 2033 value based on CAGR] by 2033. Driven by increasing cancer prevalence and advancements in immunotherapy, this report analyzes market size, growth drivers, trends, restraints, and key players like Thermo Fisher and Roche. Explore regional breakdowns and assay types (NGS, PCR, flow cytometry) to gain insights for strategic planning.

The Immuno-Oncology Assays Kit market is booming, projected to reach $3,613.7 million by 2025, with a CAGR of 6.5% through 2033. Driven by cancer prevalence and personalized medicine, this market offers significant opportunities for key players like Thermo Fisher and Roche. Learn more about market trends, key drivers, and future growth projections.

Global Immuno Oncology Assay Market is segmented by Application (Cancer Diagnostics_Companion Diagnostics_Immunotherapy Monitoring_Personalized Medicine_Cancer Research), Type (PD-L1 Assays_Tumor Mutational Burden Assays_Immune Profiling Assays_Gene Expression Assays_Immune Cell Marker Assays), and Geography (North America_ LATAM_ West Europe_Central & Eastern Europe_ Northern Europe_ Southern Europe_ East Asia_ Southeast Asia_ South Asia_ Central Asia_ Oceania_ MEA)